Medication treatments for schizophrenia: translating research findings into better outcomes.
Publication/Presentation Date
7-1-2001
Abstract
The atypical or novel antipsychotics have advanced the treatment of schizophrenia, especially given their reduced extrapyramidal side effect liability. In this article, the authors examine a number of recently published or presented studies of the atypical antipsychotics, many of them post approval studies, that shed additional light on this class of medications. Clozapine stands alone as a medication for treatment-resistant schizophrenia, but the other first-line atypical agents appear to reduce relapse rates during maintenance treatment and to have less of a long-term risk for tardive dyskinesia. However, additional research is needed to distinguish the atypical antipsychotics from each other and to better understand their non-neurological side effects.
Volume
7
Issue
4
First Page
260
Last Page
265
ISSN
1527-4160
Published In/Presented At
Lauriello, J., & Bustillo, J. (2001). Medication treatments for schizophrenia: translating research findings into better outcomes. Journal of psychiatric practice, 7(4), 260–265. https://doi.org/10.1097/00131746-200107000-00007
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
15990533
Department(s)
Administration and Leadership
Document Type
Article